Skip to main content

Table 1 Baseline characteristics of non-valvular atrial fibrillation (AF) patients with diabetes mellitus (DM) before propensity score-based stabilized weights

From: Effectiveness, safety, and major adverse limb events in atrial fibrillation patients with concomitant diabetes mellitus treated with non-vitamin K antagonist oral anticoagulants

 NOACsNOACs (A + D+R + E) (n = 20,967)Warfarin (n = 5812)ASMD
Apixaban n = 3249Dabigatran n = 6531Edoxaban n = 1389Rivaroxaban n = 9798NOACs
Vs.
Warfarin
Age
 (Mean ± STD)76 ± 9.774 ± 9.775.4 ± 9.775.5 ± 9.775.1 ± 9.872.5 ± 11.60.2406
 < 65428 (13.2%)1114 (17.1%)196 (14.1%)1345 (13.7%)3083 (14.7%)1664 (28.6%)0.3470
 65–74976 (30%)2229 (34.1%)427 (30.7%)3033 (31%)6665 (31.8%)1446 (24.9%) 
 75–841210 (37.2%)2354 (36%)539 (38.8%)3766 (38.4%)7869 (37.5%)1848 (31.8%) 
 > 85635 (19.5%)834 (12.8%)227 (16.3%)1654 (16.9%)3350 (16%)854 (14.7%) 
Male1704 (52.5%)3800 (58.2%)756 (54.4%)5045 (51.5%)11,305 (53.9%)3080 (53%)0.0185
CHA2DS2-VASc (mean ± STD)4.7 ± 1.64.4 ± 1.64.5 ± 1.54.6 ± 1.64.5 ± 1.64.2 ± 1.80.1890
HAS-BLED (mean ± STD)3.2 ± 13 ± 13.2 ± 1.13.1 ± 13.1 ± 12.9 ± 1.20.2299
Hypertension2697 (83%)5206 (79.7%)1164 (83.8%)7922 (80.9%)16,989 (81%)4446 (76.5%)0.1109
Dyslipidemia2200 (67.7%)4102 (62.8%)1011 (72.8%)6425 (65.6%)13,738 (65.5%)3409 (58.7%)0.1419
Chronic live disease455 (14%)834 (12.8%)219 (15.8%)1345 (13.7%)2853 (13.6%)779 (13.4%)0.0060
Chronic kidney disease880 (27.1%)1164 (17.8%)425 (30.6%)2295 (23.4%)4764 (22.7%)1371 (23.6%)0.0206
Chronic lung disease413 (12.7%)739 (11.3%)165 (11.9%)1389 (14.2%)2706 (12.9%)792 (13.6%)0.0213
Gout719 (22.1%)1166 (17.9%)328 (23.6%)1994 (20.4%)4207 (20.1%)1113 (19.2%)0.0230
Congestive heart failure438 (13.5%)684 (10.5%)175 (12.6%)1324 (13.5%)2621 (12.5%)919 (15.8%)0.0951
Chronic ischemic heart disease498 (15.3%)764 (11.7%)210 (15.1%)1437 (14.7%)2909 (13.9%)844 (14.5%)0.0186
Peripheral artery disease296 (9.1%)616 (9.4%)132 (9.5%)959 (9.8%)2003 (9.6%)544 (9.4%)0.0066
Stroke730 (22.5%)1597 (24.5%)205 (14.8%)2259 (23.1%)4791 (22.9%)1034 (17.8%)0.1260
Malignancy370 (11.4%)573 (8.8%)165 (11.9%)1059 (10.8%)2167 (10.3%)574 (9.9%)0.0152
PCI330 (10.2%)417 (6.4%)149 (10.7%)868 (8.9%)1764 (8.4%)510 (8.8%)0.0129
CABG31 (1%)25 (0.4%)10 (0.7%)71 (0.7%)137 (0.7%)90 (1.6%)0.0859
History of bleeding74 (2.3%)117 (1.8%)24 (1.7%)222 (2.3%)437 (2.1%)148 (2.6%)0.0307
Use of NSAIDs918 (28.3%)1551 (23.8%)389 (28%)2581 (26.3%)5439 (25.9%)1546 (26.6%)0.0150
Use of PPI451 (13.9%)622 (9.5%)174 (12.5%)1187 (12.1%)2434 (11.6%)887 (15.3%)0.1073
Use of H2 blocker1132 (34.8%)2068 (31.7%)463 (33.3%)3201 (32.7%)6864 (32.7%)2069 (35.6%)0.0604
Use of ACEI/ARB2205 (67.9%)4470 (68.4%)955 (68.8%)6731 (68.7%)14,361 (68.5%)3984 (68.6%)0.0012
Use of beta-blocker2031 (62.5%)3769 (57.7%)925 (66.6%)5939 (60.6%)12,664 (60.4%)3754 (64.6%)0.0866
Use of verapamil or diltiazem824 (25.4%)1505 (23%)260 (18.7%)2551 (26%)5140 (24.5%)1666 (28.7%)0.0940
Use of statin1600 (49.3%)2907 (44.5%)701 (50.5%)4574 (46.7%)9782 (46.7%)2263 (38.9%)0.1564
Use of APT480 (14.8%)1383 (21.2%)140 (10.1%)1926 (19.7%)3929 (18.7%)2063 (35.5%)0.3838
Use of metformin1503 (46.3%)3320 (50.8%)584 (42%)4488 (45.8%)9895 (47.2%)2567 (44.2%)0.0608
Use of SU1214 (37.4%)2675 (41%)454 (32.7%)3574 (36.5%)7917 (37.8%)2312 (39.8%)0.0415
Use of glinide293 (9%)498 (7.6%)99 (7.1%)846 (8.6%)1736 (8.3%)714 (12.3%)0.1321
Use of acarbose323 (9.9%)654 (10%)111 (8%)924 (9.4%)2012 (9.6%)645 (11.1%)0.0493
Use of glitazone185 (5.7%)381 (5.8%)68 (4.9%)463 (4.7%)1097 (5.2%)320 (5.5%)0.0121
Use of insulin927 (28.5%)1388 (21.3%)305 (22%)2601 (26.6%)5221 (24.9%)2008 (34.6%)0.2123
Use of SGLT2i63 (1.9%)54 (0.8%)48 (3.5%)106 (1.1%)271 (1.3%)20 (0.3%)0.1054
  1. ACEI angiotensin-converting-enzyme inhibitor, AF atrial fibrillation, APT antiplatelet agent, ARB angiotensin II receptor antagonists, ASMD absolute standardized mean difference, CABG coronary artery bypass grafting, CHA2DS2-VASc congestive heart failure, hypertension, age 75 years or older, diabetes mellitus, previous stroke/transient ischemic attack, vascular disease, age 65 to 74 years, female, DM diabetes mellitus, HAS-BLED hypertension, abnormal renal or liver function, stroke, bleeding history, labile INR, age 65 years or older, and antiplatelet drug or alcohol use, INR international normalized ratio, NOAC non-vitamin K antagonist oral anticoagulant, NSAIDs non-steroidal anti-inflammatory drugs, PCI Percutaneous coronary intervention, PPI proton pump inhibitor, SGLT2i sodium glucose co-transporters 2 inhibitor, STD standard deviation, SU Sulfonylurea